Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104188 | 0.90 | HRH1 (0.47) | HRH1CCR3KCNH2HTR1DENPP2 | |
| SCHEMBL5529781 | 0.90 | HTR1D (0.51) | HRH1CCR3KCNH2CYP2D6CYP2C9 | |
| SCHEMBL4249271 | 0.89 | SMN1; SMN2 (0.49) | KCNH2HTR1DOPRK1 | |
| SCHEMBL8088928 | 0.84 | HRH1 (0.48) | HRH1CCR3KCNH2HTR1DCNR1 | |
| SCHEMBL8091683 | 0.83 | HTR1D (0.51) | HTR1DENPP2 | |
| SCHEMBL5531716 | 0.82 | HTR1D (0.49) | HRH1CCR3KCNH2HTR1DOPRK1 | |
| SCHEMBL13945423 | 0.80 | HTR1D (0.50) | HRH1CCR3KCNH2HTR1DOPRK1 | |
| SCHEMBL5532963 | 0.77 | NCF1 (0.58) | KCNH2HTR1D | |
| SCHEMBL13945372 | 0.77 | SMN1; SMN2 (0.52) | HTR1D | |
| SCHEMBL5532724 | 0.77 | SMN1; SMN2 (0.49) | HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | HRH1 708/4885CCR3 3169/4885KCNH2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.